Scribble

Price Momentum

PFE is trading in the middle of its 52-week range and above its 200-day simple moving average.
Price change

The price of PFE shares has decreased $0.16 since the market last closed. This is a 0.58% drop.
Opened at $27.75.

The stock opened $0.04 lower than its previous close.

Key terms

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Sector

Industry

Employees

Founded

Website

Key stock statistics

1-day range

52-week range

Market cap

P/E ratio

Next earnings date

Dividend yield

Ex-dividend date

Dividend pay date

Market cap: $158.39B

A market capitalization between $10 billion and $200 billion places PFE in the large capitalization category.

Key terms

Smart score

Sep 07, 2026 7:08am ET The Second Act of Biotech by TipRanks Sep 05, 2026 11:02am ET Pfizer Ramps Up Obesity And Eczema Bets, Investors Watch by TipRanks Sep 04, 2026 12:32pm ET Pfizer’s Next Move in Obesity Drugs: What the New VESPER-JM Trial Means for PFE Investors by TipRanks Sep 04, 2026 12:31pm ET Pfizer Steps Up in Obesity Race With New Phase 3 Berobenatide Trial in Japan by TipRanks Sep 04, 2026 12:30pm ET Pfizer’s Tilrekimig Eczema Trial: A Fresh Phase 3 Catalyst for PFE Investors by TipRanks Sep 04, 2026 12:30pm ET Pfizer’s Migraine Tablet Study Wraps Up, Supporting Pipeline Flexibility for PFE Investors by TipRanks Sep 03, 2026 4:30pm ET Vaxcyte names Luis Jodar chief medical officer, David McAvoy chief legal officer by TipRanks Sep 02, 2026 12:31pm ET Pfizer’s New Asthma Candidate PF-08103402 Enters Phase 1: What Investors Should Know by TipRanks Aug 31, 2026 3:36pm ET Paramount Skydance (NASDAQ:PSKY) Stock Notches Up as Paramount Calls In Legal Muscle by TipRanks Aug 29, 2026 11:03am ET Pfizer Pivots: New Trials Target Obesity, Cancer, Autoimmune by TipRanks Aug 28, 2026 4:44pm ET 3 ETFs to Buy with 10%+ Total Returns, According to the AI Analyst by TipRanks Aug 28, 2026 12:31pm ET Pfizer Extends Tucatinib Access With New Continuation Study: What Investors Should Know by TipRanks Aug 28, 2026 12:31pm ET Pfizer Expands Autoimmune Pipeline With New Early-Stage Trial of PF-08154225 by TipRanks Aug 28, 2026 12:30pm ET Pfizer Targets China’s Obesity Market With New Phase 3 Berobenatide Trial by TipRanks Aug 28, 2026 12:30pm ET Pfizer Explores Easier Injection Delivery With New Tilrekimig Phase 1 Study by TipRanks Aug 28, 2026 12:30pm ET Pfizer’s Xalkori Lung Cancer Study Update: What Investors Need to Know by TipRanks Aug 28, 2026 9:50am ET Trump Trade: U.S. nearing deal for Venezuelan oil field stake by TipRanks Aug 28, 2026 6:26am ET U.S. companies work to gain favor with Democrats, WSJ reports by TipRanks Aug 27, 2026 4:35pm ET Pfizer and BioNTech receive FDA approval for XFG-adapted COVID-19 vaccine by TipRanks Aug 27, 2026 12:30pm ET Pfizer’s Korean Vyndamax Study Update: What It Means for ATTR-CM Investors by TipRanks Aug 26, 2026 10:11am ET Trump Trade: Canada rolls out 50% tariffs on U.S. metals by TipRanks Aug 25, 2026 1:20pm ET HHS plans to add FDA deputy roles for technology, drugs, CNBC says by TipRanks Aug 24, 2026 8:18am ET Pfizer Stock (PFE) Is a Buy despite Declining Revenues by TipRanks Aug 24, 2026 7:30am ET Wall Street Analysts Are Bullish on Top Healthcare Picks by TipRanks Aug 22, 2026 11:02am ET Pfizer’s Quiet Trial Wave Hints at Big Pipeline Upside by TipRanks Aug 21, 2026 12:32pm ET Pfizer’s India Migraine Study Adds Real-World Momentum for PFE by TipRanks Aug 21, 2026 12:32pm ET Pfizer’s Atirmociclib Liver Study Adds Fresh Momentum to PFE’s Pipeline by TipRanks Aug 21, 2026 12:31pm ET Pfizer’s Real World Prostate Cancer Study Sets Up a New Test for Leading Therapies by TipRanks Aug 21, 2026 12:31pm ET Pfizer Advances PF-07248144 With Key Drug-Interaction Study Completion by TipRanks Aug 21, 2026 12:30pm ET Pfizer’s Atirmociclib Study Marks Quiet but Important Step in Pipeline Progress by TipRanks Aug 21, 2026 12:30pm ET Pfizer’s PF-07868489 PAH Study Reaches Completion, Signaling Early Pipeline Momentum by TipRanks

1-year income & revenue

Total revenue: $62.58B (1Y), $15.03B (Q2)

Total Revenue held flat since last year and increased 4.03% since last quarter.
Net income: $7.77B (1Y), -$256.00M (Q2)

Net Income decreased 3.1% since last year and decreased 109.48% since last quarter.
Earnings per share: $1.36 (1Y), -$0.04 (Q2)

EPS decreased 3.63% since last year and decreased 109.28% since last quarter.

Key terms

analyst rating

buy
hold
sell

1-year stock price forecast

$ Market cap P/E ratio $ Price 1d change 52-week range

How competitors are chosen

PFE's competitors are included in the Health Technology sector and Pharmaceuticals: Major group
Market cap: $158.39B

A market capitalization between $10 billion and $200 billion places PFE in the large capitalization category.